<DOC>
	<DOCNO>NCT01788774</DOCNO>
	<brief_summary>This clinical trial design evaluate different dosage risperidone ISM , new long-acting injectable form .</brief_summary>
	<brief_title>Pharmacokinetic , Safety , Tolerability Study Risperidone ISM® Different Dose Strengths</brief_title>
	<detailed_description>This clinical trial try characterize document pharmacokinetics risperidone ISM schizophrenic schizoaffective patient one intramuscular injection different dose strengths.Likewise , safety tolerability risperidone ISM evaluate mentioned population . Following confirmation eligibility washout period study-prohibited drug , total 33 subject randomize 1:1:1 ratio receive single intramuscular ( IM ) injection one following dosage study drug : Group 1 : 50 mg risperidone ISM Group 2 : 75 mg risperidone ISM Group 3 : 100 mg risperidone ISM Several blood sample plasma pharmacokinetic ( PK ) assessment obtain pre-dose post-dose . Safety assessment conduct pre-specified time point .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Capable providing inform consent . Male female age ≥ 18 year &lt; 65 year Current diagnosis schizophrenia schizoaffective disorder , accord Structured Clinical Interview Diagnostic Statistical Manual Mental Disorders Clinical Trials ( SCIDCT ) DSMIVTR Medically stable last month , psychiatrically stable without significant symptom exacerbation last three month base investigator 's judgment Score ≤ 4 ( moderately ill ) Clinical Global Impression Severity Illness ( CGIS ) If sexually active female childbearing potential , use medically accept contraceptive method . Presence uncontrolled , unstable , clinically significant medical condition opinion investigator may interfere interpretation safety PK evaluation If female , positive serum pregnancy test , plan become pregnant one month last dose trial medication , currently breastfeed child History neuroleptic malignant syndrome current past history tardive dyskinesia Positive urine drug/alcohol screen find , unless positive finding account documented prescription use . In investigator 's opinion , imminent risk commit selfharm Use depot antipsychotic within last three month Receipt investigational drug within last three month Current participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Risperidone ISM®</keyword>
	<keyword>Intramuscular</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>